Dr. Chul Kim
Claim this profileMedStar Georgetown University Hospital
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
17 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Chul Kim is currently running
Sacituzumab Govitecan
for Thymic Cancer
The goal of this clinical trial is to study the effect of sacituzumab govitecan-hziy in adult patients with advanced thymoma and thymic carcinoma after progressing on at least one prior line of therapy. The main question it aims to answer is: • What is the overall response rate (ORR) in patients with advanced thymoma and thymic carcinoma? Participants will: * receive a fixed dose of 10 mg/kg given intravenously, once weekly on Days 1 and 8 of continuous 21-day treatment cycles until disease progression or unacceptable toxicity * have regular blood tests, scans, and examinations to monitor their health. * have blood and a biopsy of their tumor for research purposes.
Recruiting1 award Phase 2
Osimertinib
for Non-Small Cell Lung Cancer
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Recruiting1 award Phase 242 criteria
More about Chul Kim
Clinical Trial Related3 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Chul Kim has experience with
- LYL797
- Durvalumab
- Tremelimumab
- Platinum-based Chemotherapy
- Sacituzumab Govitecan
- MGC018
Breakdown of trials Chul Kim has run
Lung Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Colorectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Chul Kim specialize in?
Chul Kim focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Chul Kim currently recruiting for clinical trials?
Yes, Chul Kim is currently recruiting for 7 clinical trials in Washington District of Columbia. If you're interested in participating, you should apply.
Are there any treatments that Chul Kim has studied deeply?
Yes, Chul Kim has studied treatments such as LYL797, Durvalumab, Tremelimumab.
What is the best way to schedule an appointment with Chul Kim?
Apply for one of the trials that Chul Kim is conducting.
What is the office address of Chul Kim?
The office of Chul Kim is located at: MedStar Georgetown University Hospital, Washington, District of Columbia 20007 United States. This is the address for their practice at the MedStar Georgetown University Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.